EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model

Kei Yaginuma, Kazuhiro Takahashi, Seiji Hoshi, Taiki Joho, Saki Shimoyama, Naoko Hasegawa, Koki Hasegawa, Songji Zhao, Naoyuki Ukon, Syunta Makabe, Satoru Meguro, Akifumi Onagi und 7 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-06945-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Kei Yaginuma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. Hauptthemen laut MEDLINE: Astatine, Glutamate Carboxypeptidase II, Prostatic Neoplasms, Antigens, Surface. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI Grant, Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake, Japanese Urological Association Young Researcher Promotion Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted alpha therapy is considered a promising alternative treatment for metastatic castration-resistant prostate cancer (mCRPC). Though astatine-211 (211At) is potentially useful alpha-emitter producible by cyclotrons, its clinical application has been limited by instability and a tendency to deastatination in vivo. To overcome these challenges, we developed [211At]At-NpG-PSMA, a novel PSMA ligand with a neopentyl-glycol structure that enhances in vivo stability against deastatination. This study aimed to evaluate the stability, anti-tumour effect, and safety of [211At]At-NpG-PSMA in mice. METHODS: Xenograft models were prepared by subcutaneous transplantation of PSMA-positive PC-3 PIP cells into BALB/c nu/nu mice. [211At]At-NpG-PSMA was administered to assess biodistribution, and the anti-tumour effect was evaluated at doses of 0.32, 1.00 and 1.93 MBq in comparison with saline. Histopathological examinations were performed to evaluate damage to normal organs. RESULTS: [211At]At-NpG-PSMA demonstrated high tumour uptake (42.0 ± 13.1%ID/g at 3 h) with minimal uptake in non-target tissues, including thyroid, stomach and salivary grands (0.28 ± 0.20%ID, 0.71 ± 0.12%ID/g and 0.88 ± 0.10%ID/g at 3 h, respectively). A dose-dependent anti-tumour effect was observed, with tumour volumes increasing by 796.0 ± 437.6% in the control versus 161.0 ± 213.4%, -76.4 ± 19.2% and - 59.5 ± 41.6% in the 0.32, 1.00 and 1.93 MBq groups, respectively, by day 15. Mild renal tubule regeneration was noted in the 1.00 MBq group. CONCLUSION: [211At]At-NpG-PSMA demonstrated significant stability in vivo and anti-tumour effects with minimal side effects, indicating its potential as a new therapeutic drug for PSMA-targeted alpha therapy in mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstatineGlutamate Carboxypeptidase IIProstatic NeoplasmsAntigens, SurfaceSafetyAnimalsMaleMiceHumansLigandsXenograft Model Antitumor AssaysTissue DistributionRadiopharmaceuticalsMice, Inbred BALB CCell Line, TumorDrug StabilityPC-3 Cells

Stichwörter der Autor:innen

Astatine-211Metastatic castration-resistant prostate cancerNeopentyl glycol structurePreclinical evaluationProstate-specific membrane antigenTargeted alpha therapy

Substanzen

AstatineLigandsGlutamate Carboxypeptidase IIAstatine-211Antigens, SurfaceFOLH1 protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Advanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. ykojima@fmu.ac.jp.

Förderung

  • JSPS KAKENHI Grant
  • Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake
  • Japanese Urological Association Young Researcher Promotion Grant
  • Kobayashi Foundation for Cancer Research
  • Takeda Science Foundation

Zitieren

APA

Yaginuma, K., Takahashi, K., Hoshi, S., Joho, T., Shimoyama, S., Hasegawa, N., Hasegawa, K., Zhao, S., Ukon, N., Makabe, S., Meguro, S., Onagi, A., Matsuoka, K., Ogawa, S., Uemura, M., Yamashita, T., Suzuki, H., Uehara, T., & Kojima, Y. (2025). Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06945-x

Vancouver

Yaginuma K, Takahashi K, Hoshi S, Joho T, Shimoyama S, Hasegawa N, et al. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06945-x

BibTeX
@article{Yaginuma2025,
  author = {Yaginuma, Kei and Takahashi, Kazuhiro and Hoshi, Seiji and Joho, Taiki and Shimoyama, Saki and Hasegawa, Naoko and Hasegawa, Koki and Zhao, Songji and Ukon, Naoyuki and Makabe, Syunta and Meguro, Satoru and Onagi, Akifumi and Matsuoka, Kanako and Ogawa, Soichiro and Uemura, Motohide and Yamashita, Tomoki and Suzuki, Hiroyuki and Uehara, Tomoya and Kojima, Yoshiyuki},
  title = {Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-06945-x}
}
Kostenlos starten →